<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001027</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 189</org_study_id>
    <secondary_id>11164</secondary_id>
    <nct_id>NCT00001027</nct_id>
  </id_info>
  <brief_title>A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole</brief_title>
  <official_title>A Phase I/II Trial of Parenteral Pentamidine for PCP Prophylaxis in HIV-Infected Children Who Are Intolerant to Oral Trimethoprim-Sulfamethoxazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujisawa Pharmaceutical Co</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Primary: To compare the pharmacokinetics of biweekly and monthly dose regimens of intravenous&#xD;
      pentamidine in HIV-infected infants and children who require PCP prophylaxis and who are&#xD;
      intolerant to oral trimethoprim - sulfamethoxazole. To determine the safety and tolerance of&#xD;
      these regimens in this patient population.&#xD;
&#xD;
      Secondary: To obtain information on the rate of PCP breakthrough in infants and children&#xD;
      receiving parenteral pentamidine prophylaxis.&#xD;
&#xD;
      Prophylaxis against Pneumocystis carinii pneumonia is recommended for all HIV-infected&#xD;
      children considered to be at high risk. In children younger than 5 years of age with&#xD;
      intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful&#xD;
      alternative.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prophylaxis against Pneumocystis carinii pneumonia is recommended for all HIV-infected&#xD;
      children considered to be at high risk. In children younger than 5 years of age with&#xD;
      intolerance to trimethoprim - sulfamethoxazole, parenteral pentamidine may be a successful&#xD;
      alternative.&#xD;
&#xD;
      Thirty-two children are randomized to one of two treatment arms. Patients receive pentamidine&#xD;
      on either a biweekly or a monthly treatment schedule. Treatment continues until the last&#xD;
      child enrolled has received at least 6 months of pentamidine. Patients are stratified&#xD;
      according to age &lt; 24 months or age &gt;= 24 months. Steady-state pharmacokinetics will be&#xD;
      examined in a subsample of 20 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Steroids and intravenous immune globulin (IVIG).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  Need for PCP prophylaxis.&#xD;
&#xD;
          -  Known intolerance to trimethoprim - sulfamethoxazole (TMP-SMX).&#xD;
&#xD;
        One of the following required conditions:&#xD;
&#xD;
          -  Known intolerance or allergy to dapsone; G6PD deficiency; history of serious or&#xD;
             life-threatening reaction to TMP-SMX; exclusion from protocol ACTG 179; election by&#xD;
             parent not to enroll child on ACTG 179; or receiving medical care at sites not&#xD;
             participating in ACTG 179.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Co-enrollment in other ACTG pediatric studies is permitted.&#xD;
&#xD;
        Consent of parent or guardian is required.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior pentamidine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Active PCP.&#xD;
&#xD;
          -  Pancreatitis defined as amylase elevation associated with an elevated lipase that is &gt;&#xD;
             2 x upper limit of normal.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  TMP-SMX or dapsone within 7 days prior to study entry (toxicities to TMP-SMX or&#xD;
             dapsone must be clearly resolving).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Van Dyke R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Pramberg J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. &amp; Research Ctr. Oakland, Ped. Clinical Research Ctr. &amp; Research Lab.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr., ACTU</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

